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Primary lung cancer is the second most commonly 
occurring cancer and the most common cause of cancer 
deaths worldwide (1). Non-small cell lung cancer comprises 
approximately 80% of all lung cancers. Surgery is the 
mainstay of treatment for non-small cell lung cancer, 
especially in the early stages, with lobectomy as the accepted 
standard (2). Increasing adoption of thoracoscopic surgery 
for this purpose has been observed over the previous two 
decades (3); the reported advantages of thoracoscopic 
lobectomy compared with open lobectomy include shorter 
chest tube durations, shorter hospital stays, decreased 
postoperative pain, and lower morbidity (3-5).
Antiplatelet agents (APAs) are the most frequently prescribed 
medications for a variety of conditions including coronary artery 
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occlusive disease, cerebrovascular disease, atrial fibrillation, 
peripheral artery occlusive disease (PAOD), prevention of 
venous thromboembolism, and primary prevention in high-
risk patients (6). The Antithrombotic Trialists’ Collaboration 
reported that APAs reduced the combined outcomes of any 
serious vascular event by approximately one quarter (non-
fatal myocardial infarction by one third, non-fatal stroke by 
one quarter, and vascular mortality by one sixth) (7). As a 
result, surgeons frequently encounter patients who have been 
administered antiplatelet therapy preoperatively.
Concern regarding excessive perioperative bleeding has led 
to the general recommendation that APAs be discontinued 
7-10 days preoperatively. However, withdrawal of APAs 
could increase the risk of perioperative cardiovascular events 
(8-10). The 2012 update to the Society of Thoracic Surgeons 
guidelines on the use of antiplatelet drugs in patients 
having cardiac and noncardiac operations recommends 
that continuing antiplatelet monotherapy is feasible and 
continuing dual antiplatelet therapy can be feasible in patients 
undergoing noncardiac surgery unless the risk of bleeding is 
prohibitive (11). However, studies regarding the safety 
of continuing APA treatment in general thoracic surgery, 
especially minimally invasive surgery, are rare.
This retrospective study was conducted to evaluate the safety, 
with regard to bleeding risk, and operative characteristics, with 
regard to extent of resection and dissection, of thoracoscopic 
surgery without interruption of APA.
Patients and methods
Patients
This retrospective study was approved by the institutional 
review board of the hospital (4-2014-0999) and the need 
for consent from individual patients was waived. Between 
January 2009 and February 2015, 1,384 patients underwent 
thoracoscopic surgery for curative resection of lung cancer, 
not including those who underwent wedge resection. Of 
the 164 patients that were taking APAs when the need for 
surgery was determined, the decision about interruption 
of APA for each patient was made by the surgeon, in 
consultation with the anesthesiologist, cardiologist, and 
neurologist, based on the risk of perioperative thrombotic 
events and bleeding. The medical records of these 164 
patients were reviewed retrospectively.
Operative technique and postoperative care
In our institution, thoracoscopic lobectomy has been performed 
since 2005, and more than half of the resections for lung cancer 
are now performed by thoracoscopy. Thoracoscopic lobectomy 
or segmentectomy was performed with a 3-5 cm utility incision 
at the anterior axillary line of the fourth or fifth intercostal space 
using endoscopic instruments, without spreading the ribs, and 
2-3 ports for the camera, stapler, and assistant. The operation 
was performed entirely with thoracoscopic visualization (12). 
Ultrasonic dissectors were used in most of the patients for tissue 
dissection and division.
One or two chest tubes were placed after the operation. 
Postoperative pain control was achieved using patient-
controlled intravenous analgesia and supplemental intravenous 
opioids. An epidural was not used. APAs were readministered 
from postoperative day 1, if there was no postoperative 
bleeding complication. The last chest tube was removed when 
the amount of drainage was <250 mL/day and in the absence 
of air leaks and chyle leakage.
Perioperative cardiac risk
The perioperative cardiac risk was calculated by the authors 
using Lee’s revised cardiac risk index (rCRI) (13), which 
includes six clinical variables: high-risk surgery type (because 
intrathoracic procedures are classified as high-risk surgeries 
in the rCRI, all surgeries in this study were classified as 
high risk), history of ischemic heart disease, history of 
congestive heart failure, history of cerebrovascular disease, 
preoperative treatment with insulin, and preoperative serum 
creatinine >2.0 mg/dL.
Outcome measures
Intra/postoperative outcomes for safety comparisons 
included operating time, estimated blood loss, need for 
transfusion, amount and duration of chest tube drainage, 
length of hospital stay, change in hemoglobin, postoperative 
morbidity, and postoperative mortality. The change in 
hemoglobin excluded patients who received a transfusion 
with red blood cells during the operation or within 24 hours 
after the operation and was calculated as: hemoglobin on 
postoperative day 1—preoperative hemoglobin. To compare 
the oncological quality of the surgery, the extent of lung 
resection and lymph node dissection, number of dissected 
lymph nodes, and rate of complete resection were recorded.
Statistical analysis
Continuous data are expressed as median (range) and 
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categorical data as n (percentage). The patients were placed 
into two groups for comparisons: preoperatively interrupted 
APA administration (group I) and continued APA 
administration (group N). Within group N, comparisons 
were also conducted between those administered aspirin 
+ clopidogrel and those administered other APAs (aspirin 
only, clopidogrel only, other single APA, and aspirin + other 
APA). Continuous variables were compared between the 
groups using the Mann-Whitney U test, and categorical 
variables were compared using the Chi-squared tests or 
Fisher’s exact tests. All tests were two-sided, and a P value 
<0.05 was considered statistically significant. All statistical 
analyses were performed using SPSS version 20.0 (IBM 
Corp., Armonk, NY, USA).
Results
Baseline characteristics
Group I consisted of 106 patients (64.6%), with a 
median duration of APA interruption of 9 [2-50] days. 
Group N consisted of 58 (35.3%) patients. The baseline 
characteristics of the patients are summarized in Table 1. 
Group N had significantly higher rCRI scores (P=0.001). 
Significantly more patients in group N were administered 
Table 1 Baseline characteristics of patients with lung cancer who underwent thoracoscopic surgery, comparing those with and without 
interrupted antiplatelet agent administration
Characteristics Non-Interruption (n=58) Interruption (n=106) P
Age (years) 69 [51-83] 70 [52-85] 0.890
Sex
Male 39 (67.2) 67 (68.5) 0.605
BMI (kg/m2) 24.47 (18.72-32.89) 24.01 (18.74-32.89) 0.340
Smoking 39 (67.2) 63 (59.4) 0.324
Pack-years 31 [0-90] 14.35 [0-85] 0.083
FEV1 (%) 95 [61-147] 101 [58-153] 0.133
ECOG 0 [0-2] 0 [0-1] 0.357
Preoperative chemotherapy 1 (1.7) 1 (0.9) >0.999
Antiplatelet agent
Aspirin 44 (75.9) 85 (80.2) 0.518
Clopidogrel 18 (31.0) 17 (16.0) 0.025
Aspirin + clopidogrel 11 (19.0) 6 (5.7) 0.008
Othera 9 (15.5) 13 (12.3) 0.559
rCRI 2 [1-4] 1 [1-3] 0.001
Indication for antiplatelet therapy
Ischemic heart disease 28 (48.3) 29 (27.4) 0.007
CABG 6 (10.3) 5 (4.7) 0.199
PCI 14 (24.1) 9 (8.5) 0.006
Cerebrovascular disease 15 (25.9) 22 (20.8) 0.454
Atrial fibrillation 5 (8.6) 7 (6.6) 0.756
PAOD 3 (5.2) 2 (1.9) 0.347
Primary prevention 15 (25.9) 60 (56.6) <0.001
Interruption duration (days) 9 [2-50]
a, other antiplatelet agents included cilostazol (n=8), sarpogrelate (n=7), and triflusal (n=7). Data are expressed as median (range) 
or n (%). BMI, body mass index; CABG, coronary artery bypass graft; ECOG, eastern cooperative oncology group; FEV1, forced 
expiratory volume in 1 second; PAOD, peripheral artery occlusive disease; PCI, percutaneous coronary intervention; rCRI, revised 
cardiac risk index.
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clopidogrel (P=0.025) or aspirin + clopidogrel (P=0.008). 
Significantly more patients in group I were administered 
APAs for primary intervention (P<0.001). Significantly more 
patients in group N had ischemic heart disease (P=0.007) 
and underwent percutaneous coronary intervention (PCI) 
(P=0.006).
Characteristics of lung cancer and operation parameters
Characteristics of lung cancer and operative data are 
summarized in Tables 2,3. The groups were not significantly 
different in terms of lung cancer characteristics or extent 
of lung resection and lymph node dissection, number of 
dissected lymph nodes, rate of complete resection, rate 
of thoracotomy conversion, rate of transfusion, amount 
of blood loss during the operation, or operating time. 
Thoracotomy conversion was performed because of 
bleeding from the pulmonary artery in 4 patients (2 in each 
group), descending thoracic aorta rupture by linear stapler 
tip in 1 patient (group N), invasion to mediastinal pleura by 
tumor in 1 patient (group I) and severe pleural adhesion in 
1 patient (group I).
Postoperative outcomes
Postoperative outcomes are described in Table 4. The groups 
were not significantly different in the number of patients 
requiring transfusion within 30 days postoperatively, change 
in hemoglobin, amount of chest tube drainage over a period 
of 3 days, the length of hospital stay, postoperative bleeding 
and thrombotic complications, or operative mortality. 
Duration of chest tube drainage was little longer in patient 
group N (4 days in group N vs. 3.5 day in group I, P=0.036).
Postoperative bleeding occurred in 5 patients (3 in 
Table 2 Characteristics of lung cancer in patients who underwent thoracoscopic surgery, comparing those with and without interrupted 
antiplatelet agent administration
Characteristics Non-interruption (n=58) Interruption (n=106) P
Location of tumor 0.081
RUL 18 (31.0) 28 (26.4)
RML 4 (6.9) 18 (17.0)
RLL 12 (20.7) 18 (17.0)
LUL 17 (29.3) 18 (17.0)
LLL 7 (12.1) 24 (22.6)
Histology 0.250
Adenocarcinoma 38 (65.5) 80 (75.5)
Squamous cell carcinoma 18 (31.0) 21 (19.8)
Other 2 (3.4) 5 (4.7)
pTstage 0.770
0 0 (0.0) 1 (0.9)
is 0 (0.0) 3 (2.8)
1a 26 (44.8) 37 (34.9)
1b 11 (19.0) 25 (23.6)
2a 16 (27.6) 32 (30.2)
2b 2 (3.4) 2 (1.9)
3 3 (5.2) 6 (5.7)
pNstage 0.422
0 53 (91.4) 89 (84.0)
1 2 (3.4) 8 (7.5)
2 3 (1.8) 9 (8.5)
LLL, left lower lobe; LUL, left upper lobe; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe. Data are expressed as n (%).
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Table 3 Operative characteristics of thoracoscopic surgery in patients with lung cancer, compared between those with and without  
interrupted antiplatelet agent administration
Operative characteristics Non-interruption (n=58) Interruption (n=106) P
Extent of resection 0.496
Bilobectomy 0 (0.0) 3 (2.8)
Lobectomy 52 (89.7) 95 (89.6)
Segmentectomy 6 (10.3) 8 (7.5)
Extent of LN dissection 0.423
LN sampling 1 (1.7) 6 (5.7)
LN dissection 57 (98.3) 100 (94.3)
Number of dissected LN 27.5 [7-47] 26 [5-57] 0.375
Complete resection (R0) 57 (98.3) 102 (96.2) 0.657
Adhesion 23 (39.7) 39 (36.8) 0.718
Thoracotomy conversion 3 (5.2) 4 (3.8) 0.699
Intraoperative transfusion 2 (3.4) 2 (1.9) 0.615
Blood loss (mL) 50 (10-2,900) 50 [10-3,900] 0.158
Bleeding >500 cc 5 (8.6) 3 (2.8) 0.132
Operating time (min) 136 [54-307] 141 [60-360] 0.265
LN, lymph node. Data are expressed as median (range) or n (%).
Table 4 Postoperative outcomes of thoracoscopic surgery in patients with lung cancer, comparing those with and without interrupted  
antiplatelet agent administration
Postoperative outcomes Non-interruption (n=58) Interruption (n=106) P
Postoperative transfusion (within 30 days postoperative) 5 (8.6) 3 (2.8) 0.132
∆Hb (mg/dL) −1.10 (−5.20-2.10) −1.00 (−3.30-1.70) 0.592
Chest tube drainage over a 3-day period (mL) 695 (140-2,280) 720 (90-3,080) 0.870
Duration of chest tube (days) 4 [2-114] 3.5 [1-18] 0.036
Length of hospital stay (days) 6 [3-140] 5 [2-19] 0.064
Postoperative complications (all) 13 (22.4) 14 (13.2) 0.129
Bleeding complication 3 (5.2) 3 (2.8) 0.667
Postoperative bleeding 3 (5.2) 2 (1.9) 0.357
Postoperative bleeding requiring reoperation 0 (0.0) 1 (0.9) >0.999
Bronchopulmonary hemorrhage 0 (0.0) 1 (0.9) >0.999
Cerebrovascular accident 1 (1.7) 0 (0.0) 0.354
Pneumonia 5 (8.6) 3 (2.8) 0.132
Prolonged air leak (>7 days) 3 (5.2) 3 (2.8) 0.667
Bronchopulmonary fistula 2 (3.4) 0 (0.0) 0.124
Vocal cord palsy 1 (1.7) 2 (1.9) >0.999
Chylothorax 0 (0.0) 1 (0.9) >0.999
Wound dehiscence 0 (0.0) 2 (1.9) 0.540
Readmission 1 (1.7) 2 (1.9) >0.999
Operative mortality 1 (1.7) 0 (0.0) 0.354
∆Hb, hemoglobin on postoperative day 1—preoperative hemoglobin, excluding patients who received a transfusion with red 
blood cells during the operation or within 24 hours after the operation (n=7). Data are expressed as median (range) or n (%).
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group N, 2 in group I; 1 reoperation was performed in 
the group I patient. The other patients were managed 
conservatively). One patient in group I experienced 
hemoptysis,  with pulmonary infi ltration on chest 
radiography (bronchopulmonary hemorrhage). He 
recovered without intervention and was discharged on 
postoperative day 11. There was one cerebrovascular 
accident in a group N patient who was administered aspirin 
+ clopidogrel preoperatively for a cerebral infarction. 
Neurologic deficit was apparent immediately after the 
operation and acute cerebral infarction was confirmed using 
brain magnetic resonance imaging. There were no other 
cardiac or thrombotic complications.
Operative mortality occurred in one patient in group N. 
After the right lower lobe lobectomy, he was discharged 
on postoperative day 7 without any complications. 
He was readmitted with pneumonia, empyema, and a 
bronchopulmonary fistula on postoperative day 14 and died 
on postoperative day 89.
Table 5 provides the results of the comparisons between 
aspirin + clopidogrel and other APAs within group N. 
Patients administered aspirin + clopidogrel had significantly 
more postoperative bleeding (P=0.005), more chest tube 
drainage over a 3-day period (P=0.028), longer duration 
of chest tube drainage (P=0.028), and longer hospital stays 
(P=0.030). In addition, more patients required postoperative 
transfusion (P=0.001). Reoperation for bleeding was not 
required in any of the patients.
Transfusion was required for eight patients during and/
or within 30 days after the operation (group I, n=3; group N, 
n=5) (Table 6). Most of these patients had pleural adhesion.
Discussion
The present results indicate that thoracoscopic surgery for 
lung cancer without interruption of APAs can be performed 
without an increase in the thoracotomy conversion rate, 
operating time, estimated blood loss during the operation, 
transfusion requirement, or postoperative bleeding 
complications.
APAs are administered for a variety of conditions, 
including coronary artery occlusive disease, cerebrovascular 
disease, atrial fibrillation, PAOD, prevention of venous 
thromboembolism, and primary prevention in high-risk 
patients (6). In the present study, approximately 10% of 
the patients who underwent thoracoscopic surgery for 
lung cancer were taking APAs, while in a population-based 
cohort study, approximately 26% of patients diagnosed with 
lung cancer were aspirin users (14). Concerns regarding 
the discontinuation of APAs include the resulting rebound 
Table 5 Outcomes in patients with lung cancer who underwent thoracoscopic surgery, comparing those administered aspirin +  
clopidogrel and those who received other single or dual antiplatelet agents
Outcomes Aspirin + clopidogrel (n=11) Other than aspirin + clopidogrela (n=47) P
Blood loss during operation (mL) 145 [10-1,300] 50 [10-2,900] 0.441
Blood loss during operation (>500 mL) 2 (18.2) 3 (6.4) 0.237
Intraoperative transfusion 0 (0.0) 2 (4.3) >0.999
Operating time (min) 130 [94-307] 137 [54-307] 0.743
Postoperative transfusion (within 30 days after operation) 4 (36.4) 1 (2.1) 0.003
∆Hb (mg/dL) −1.5 (−5.2-2.1) −1.0 (−5.1-1.4) 0.571
Chest tube drainage over a 3-day period (mL) 1,140 (430-2,280) 690 [140-2,030] 0.049
Duration of chest tube (days) 5 [3-14] 4 [2-114] 0.095
Length of hospital stay (days) 6 [4-18] 5 [3-140] 0.154
Postoperative bleeding 3 (27.3) 0 (0.0) 0.005
Cerebrovascular accident 1 (9.1) 0 (0.0) 0.190
Postoperative complications (all) 4 (36.4) 9 (19.1) 0.244
a, this group included aspirin only (n=32), clopidogrel only (n=6), other single APA (n=7), aspirin + other APA (n=1), and clopidogrel  
+ other APA (n=1); ∆Hb, hemoglobin on postoperative day 1—preoperative hemoglobin, excluding patients who received a  
transfusion with red blood cells during the operation or within 24 hours after the operation (n=4). Data are expressed as median 
(range) or n (%).
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Table 6 Characteristics of transfused patients with lung cancer who underwent thoracoscopic surgery
Patient
Age 
(years)
Sex Procedure
Antiplatelet 
agent
Interruption 
(duration)
Intraoperative 
event(s)
Thoracotomy 
conversion
Transfusiona  
(intraoperative/ 
postoperative)
Reoperation 
for bleeding
Hospital 
stay (days)
1 78 M RML  
lobectomy
Aspirin, 
clopidogrel
Yes  
(16 days)
PA tearing Yes 5-2-0/2-4-0 No 12
2 72 M LLL  
lobectomy
Aspirin Yes  
(14 days)
Pleural adhesion Yes 1-0-0/3-0-0 No 8
3 62 F RML  
lobectomy
Aspirin, 
clopidogrel
Yes  
(3 days)
No No 0-0-0/5-2-6 Yes 5
4 78 F LUL  
lobectomy
Aspirin No Pleural adhesion, 
PA tearing
Yes 5-0-0/0-0-0 No 10
5 72 M RUL  
lobectomy
Aspirin, 
clopidogrel
No Pleural adhesion, 
PA tearing
Yes 0-0-0/2-0-0 No 11
6 60 M RUL  
lobectomy
Aspirin, 
clopidogrel
No Pleural adhesion, 
pleural tenting
No 0-0-0/3-0-0 No 6
7 71 F RUL  
lobectomy
Aspirin, 
clopidogrel
No Pleural adhesion No 0-0-0/0-0-6 No 5
8 73 M RUL  
lobectomy
Aspirin, 
clopidogrel
No Pleural adhesion No 0-0-0/0-2-0 No 18
9 64 M LLL  
lobectomy
Aspirin No Pleural adhesion 
descending  
thoracic aorta 
rupture
Yes 5-3-0/1-2-0 No 140
a, transfused blood products are shown as packed red blood cells-fresh frozen plasma-platelets. LLL, left lower lobe; LUL, left  
upper lobe; PA, pulmonary artery; RLL, right lower lobe; RML, right middle lobe; RUL, right upper lobe.
effect and potentially increased coagulability from a systemic 
inflammatory reaction to surgery. The average postoperative 
myocardial infarction rate and mortality due to stent 
thrombosis during the re-endothelialization phase of a 
coronary stent are reportedly 35% and 20-40%, respectively. 
In addition, the treatment for postoperative myocardial 
infarction, including emergency PCI and thrombolysis, is 
more difficult and is associated with greater risk (15).
Aspirin does not appear to significantly increase 
bleeding complications (16,17), based on the results of two 
randomized clinical trials. The first, a multicenter, blinded 
study regarding the impact of preoperative maintenance 
or interruption of aspirin on thrombotic and bleeding 
events after non-cardiac surgery reported no differences in 
bleeding events between the aspirin (n=145) and placebo 
(n=146) groups at postoperative day 7 (n=9, 6.2% and n=8, 
5.5%, respectively, P=0.81) or day 30 (n=10, 6.9% and 
n=10, 6.8%, respectively, P=0.99) (16). In the second, a 
double-blind study involving 220 patients, a 7.2% absolute 
risk reduction (95% confidence interval, 1.3-13%) in 
postoperative major adverse cardiac events was observed, 
without an increase in bleeding complications. Interestingly, 
a subjective assessment of intraoperative bleeding by the 
attending surgeon indicated no difference between the 
aspirin and placebo groups (17).
The effects  of  c lopidogrel  have typical ly  been 
investigated for cardiac surgeries, resulting in increased 
blood loss, reoperations for bleeding, transfusion rate, and 
length of stay in the intensive care unit (15,18,19). However, 
in the study regarding the safety of general thoracic surgery 
in patients taking clopidogrel by Cerfolio et al., the risk of 
bleeding after primary thoracotomy or minimally invasive 
thoracic surgery was not increased (20). Although 12 
lobectomies (11 open, 1 robot-assisted) and 6 thoracoscopic 
procedures were included, none of the patients underwent 
thoracoscopic lobectomy.
In addition to the reported advantages of shorter 
chest tube durations, shorter hospital stays, decreased 
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postoperative pain, and lower morbidity with thoracoscopic 
lobectomies (3-5), decreased blood loss during the 
operation has also been reported (12). A few studies have 
recently reported that minimally invasive surgery in other 
surgical areas could be safely performed in patients taking 
APAs without an increase in bleeding complications (21,22). 
To the best of our knowledge, the present study is the 
first to suggest that a complex thoracoscopic procedure 
such as lobectomy can be performed safely, without 
increasing bleeding complications, blood loss, transfusion 
requirements, perioperative morbidity, or mortality.
In the present study, continuation of aspirin + clopidogrel 
was associated with increased postoperative bleeding, 
transfusion requirements, amount of chest tube drainage over 
a period of 3 days, duration of chest tube drainage, and length 
of hospital stay. Of the 11 patients taking aspirin + clopidogrel, 
4 (36.4%) patients received transfusions postoperatively, and 
all had severe pleural adhesions (Table 6). This is consistent 
with the results of the study by Cerfolio et al., in which 
patients administered both aspirin and clopidogrel who 
underwent a redo thoracotomy for subsequent lung cancer 
needed reoperation because of postoperative bleeding. It 
appears to be more difficult to control bleeding from the chest 
wall secondary to the takedown of adhesions in patients taking 
aspirin + clopidogrel (20).
This study has several limitations. It was a retrospective 
study performed in a single institution with a small sample 
of patients. Patents of group N seem to have more cardiac 
or thrombotic risk and they could be performed simpler 
procedure for lung cancer. In fact, patients continuing 
clopidogrel tend to have recent cerebrovascular diasease, 
recent PCI or CABG, or multiple risk factor (Table S1). 
Because of  the smal l  sample of  pat ients  and few 
thromboembolic events, the effect of continued use APAs on 
perioperative thromboembolic events cannot be evaluated. 
In addition, we only compared postoperative outcomes but 
not the long-term oncologic outcomes of the perioperative 
use of APAs. However, there were no differences in the 
extent of resection and lymph node dissection, rate of 
complete resection, or number of dissected lymph nodes 
between the groups.
In conclusion, continued use of APAs during thoracoscopic 
surgery for lung cancer could be safely done in patients 
at high risk of cardiac or thrombotic events. However, in 
patients administered aspirin + clopidogrel, it may be the 
best to continue aspirin only because of an increased risk of 
postoperative bleeding and transfusion requirements.
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